Clazakizumab

Clazakizumab has been studied in 3 papers since 2026: none in people yet, 2 reviews; 3 in the past year. No study of it in people or animals has been published yet. The newest paper, Aug 25, 2026: “Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies”.

Intervention

3 papers study it1 findingUpdated

See all 3 papers on clazakizumab

At a glance

4 trials, none about aging.

Cells, worms or flies, mice and humans: nothing yet.
  • 4 trials, none about aging
  • 3 of 4 trials sponsored by its developers

What did studies of clazakizumab find?

1

Studies of clazakizumab measured one outcome, inflammatory biomarkers.

Inflammatory biomarkers

downin humans1

1 study
  1. Clazakizumab decreases inflammatory biomarkers in humans.

    Review

More on Inflammatory biomarkers

Who is developing clazakizumab?

2 companies: CSL Behring and Eli Lilly.

Companies
  • CSL BehringPhase 2/3end stage kidney disease
  • Eli LillyPhase 2atherosclerosis, cardiovascular disease

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 0Oct 2026: 0Nov 2026: 03 papers in 12 months